Bladder Tumor Cryoablation Solution

Clinical Pain Points

Conventional transurethral resection (TURBT) combined with intravesical chemotherapy presents six major clinical shortcomings:
Intraoperative Safety Risks– Resection of lateral wall tumors may trigger obturator nerve reflex, causing instrument loss of control that can lead to bladder perforation and pelvic massive hemorrhage. The electrical current generated during resection may interfere with implantable devices, limiting the patient population eligible for this procedure.
Significant Intraoperative Bleeding and Severe Postoperative Complications– Resection-induced vascular injury causes blurred visualization during the procedure. Postoperative eschar shedding from the resected area may lead to persistent gross hematuria and bladder clot retention, requiring secondary irrigation and prolonged catheter indwelling time.
High Risk of Tumor Seeding and Recurrence– Fragmentation of the tumor during piecemeal resection releases free cancer cells, facilitating intravesical seeding. Simple instillation of chemotherapeutic agents is inadequate to eliminate deep microscopic lesions, resulting in frequent short-term recurrence.
Intense Intraoperative Stimulation with Limited Applicability– Thermal cautery induces severe bladder spasm and lower abdominal pain, generally requiring general anesthesia. Elderly patients or those with underlying cardiopulmonary conditions face high anesthesia risks and may not tolerate the procedure.
Pronounced Side Effects from Intravesical Chemotherapy– Postoperative intravesical instillation of chemotherapeutic agents often causes severe frequency, dysuria, and chemical cystitis. Long-term repeated instillation damages normal bladder mucosa, leading to poor patient compliance.

Core Advantage

Complete Tumor Elimination– Low temperatures effectively destroy bladder tumor cells, minimizing residual disease.
Bladder Preservation with Minimal Scarring– Postoperative bladder architecture remains intact, with minimal scar formation and full preservation of the bladder wall.
Minimally Invasive and Safe– Pure physical therapy with short procedure time, few side effects, rapid recovery, and low complication rates.
Chemo-sensitization– Can be combined with chemotherapy, as cryoablation increases tumor cell permeability to chemotherapeutic agents.

Clinical Value

The Bladder Tumor Cryoablation System is an endoluminal minimally invasive device for urology. It delivers targeted cryoablation to inactivate tumors, with minimal damage to normal bladder tissue, limited intraoperative bleeding, and a low risk of bladder perforation. It is indicated for superficial multifocal and recurrent bladder tumors, and meets the bladder-preserving treatment needs of elderly or frail patients. The system is capable of eliminating occult微小 lesions and reducing tumor recurrence rates. Performed via a transurethral minimally invasive approach, it enables rapid postoperative recovery and enhances the standardized minimally invasive diagnosis and treatment framework for bladder tumors.

Solutions

Safety Solution– No electrical current, no obturator nerve reflex, effectively avoiding bladder perforation and massive hemorrhage.
Hemostasis and Recovery Solution– Low-temperature occlusion of blood vessels without carbonized eschar formation, reducing postoperative hematuria and clot retention, and shortening catheter indwelling time.
Recurrence Prevention Solution– In situ cryoablation inactivates the tumor, preventing cancer cell seeding and ensuring more thorough lesion clearance, thereby reducing recurrence rates.
Broad Patient Applicability– Mild intraoperative stimulation extends suitability to a wider patient population.

Enhanced Treatment Experience– Reduces the frequency of chemotherapy instillation, avoiding toxic side effects such as chemical cystitis, urinary frequency, and dysuria.